Prolaction levels in risperidone treatment of first - episode schizophrenia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F04%3A00025498" target="_blank" >RIV/00216224:14110/04:00025498 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Prolaction levels in risperidone treatment of first - episode schizophrenia
Original language description
Risperidone in an average dose lower than 4 mg significantly improved both positive and negative symptoms. Co-operating responders undergoing maintanance therapy showed a mild trend towards further long-term improvement. At the end of acute treatment theaverage elevation of PRL levels almost doubled the baseline value. There was a trend among responders to return to their initial values during long-term therapy. Three-quarters of the subject had hyperprolactinaemia at the end of acute treatment(44 days),and after 1 year about one-quarter had hyperprolactinaemia. No significant correlation between PRL change and PANSS score change was found.
Czech name
Hladiny prolaktinu u pacientů s první atakou schizofrenie léčených risperidonem
Czech description
Článek pojednává o studii, která mapuje vliv léčby risperidonem u pacientů s první epizodou schizofrenie na hladinu prolaktinu v krvi

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FL - Psychiatry, sexology
OECD FORD branch
—

Publication year
2004
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)